More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

immune checkpoint
James Allison and Tasuku Honjo Win Nobel Prize
James Allison and Tasuku Honjo Win Nobel Prize
Ashley Yeager, Kerry Grens | Oct 1, 2018
The immunologists, honored with the 2018 award in Physiology or Medicine, pioneered immunotherapy, which harnesses the body’s immune system to fight cancer.
Opinion: Learning from Immunotherapy’s Recent Failures
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.
Antibody Combo Expands Response to Checkpoint Inhibitor in Mice
Antibody Combo Expands Response to Checkpoint Inhibitor in Mice
Kerry Grens | Apr 16, 2018
Genetic analyses uncover cellular hallmarks of bladder cancer tumors that don’t respond, but interfering with one of those characteristics in a mouse model causes tumors to shrink.  
The Cancer Genes Needed for Immunotherapy Response
The Cancer Genes Needed for Immunotherapy Response
Anna Azvolinsky | Aug 7, 2017
Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.  
Gene Mutations Foretell Immunotherapy Response
Gene Mutations Foretell Immunotherapy Response
Aggie Mika | Jun 12, 2017
A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.